+

SG11201906297QA - Nucleic acids encoding crispr-associated proteins and uses thereof - Google Patents

Nucleic acids encoding crispr-associated proteins and uses thereof

Info

Publication number
SG11201906297QA
SG11201906297QA SG11201906297QA SG11201906297QA SG 11201906297Q A SG11201906297Q A SG 11201906297QA SG 11201906297Q A SG11201906297Q A SG 11201906297QA SG 11201906297Q A SG11201906297Q A SG 11201906297QA
Authority
SG
Singapore
Prior art keywords
international
pct
nucleic acids
associated proteins
crispr
Prior art date
Application number
Inventor
Frédéric Chevessier-Tünnesen
Marion Poenisch
Thomas Schlake
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of SG11201906297QA publication Critical patent/SG11201906297QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT 0111111010 0111 °nolo olomionwomom ois (10) International Publication Number WO 2018/172556 Al (51) International Patent Classification: C12N 15/67 (2006.01) (21) International Application Number: PCT/EP2018/057552 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/057110 24 March 2017 (24.03.2017) EP PCT/EP2017/076775 19 October 2017 (19.10.2017) EP (71) Applicant: CUREVAC AG [DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tuebingen (DE). (72) Inventors: CHEVESSIER-TUENNESEN, Frederic; Falltorstr. 36, 72116 Moessingen (DE). POENISCH, Mar- ion; Mohlstr. 38, 72074 Tuebingen (DE). SCHLAKE, Thomas; Gartenweg 1, 79194 Gundelfmgen (DE). (74) Agent: VON STOSCH, Andreas et al.; Prinzregentstr. 22, 80538 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 17 2556 Al (54) Title: NUCLEIC ACIDS ENCODING CRISPR-ASSOCIATED PROTEINS AND USES THEREOF (57) : The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.
SG11201906297Q 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof SG11201906297QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017057110 2017-03-24
EP2017076775 2017-10-19
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11201906297QA true SG11201906297QA (en) 2019-10-30

Family

ID=61801946

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202110491PA SG10202110491PA (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201906297Q SG11201906297QA (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202110491PA SG10202110491PA (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof

Country Status (11)

Country Link
US (3) US11739335B2 (en)
EP (1) EP3601576A1 (en)
JP (2) JP2020513824A (en)
KR (1) KR102842382B1 (en)
CN (1) CN110914433A (en)
AU (1) AU2018240515B2 (en)
BR (1) BR112019015244A2 (en)
CA (1) CA3050616A1 (en)
MX (1) MX2019011215A (en)
SG (2) SG10202110491PA (en)
WO (1) WO2018172556A1 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012129373A2 (en) 2011-03-23 2012-09-27 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
CA2915712A1 (en) 2013-08-21 2015-02-26 Margit SCHNEE Rabies vaccine
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN120574876A (en) 2013-08-22 2025-09-02 纳幕尔杜邦公司 Plant genome modification using guide RNA/CAS endonuclease systems and methods of use thereof
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
EP3628739B1 (en) 2014-09-12 2024-05-01 Corteva Agriscience LLC Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3708668B1 (en) 2014-12-12 2022-07-27 CureVac AG Artificial nucleic acid molecules for improved protein expression
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
DE202016009003U1 (en) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Composition comprising in vitro transcribed RNA obtainable by a method for the production and purification of RNA with at least one step with a tangential flow filtration
CN108026526B (en) 2015-06-09 2023-05-12 爱迪塔斯医药公司 CRISPR/CAS-related methods and compositions for improving transplantation
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
DK3319622T3 (en) 2015-12-22 2020-05-04 Curevac Ag PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
WO2018064352A1 (en) 2016-09-30 2018-04-05 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
MX2019003674A (en) 2016-09-30 2021-01-08 Univ California Rna-guided nucleic acid modifying enzymes and methods of use thereof.
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US10876101B2 (en) 2017-03-28 2020-12-29 Locanabio, Inc. CRISPR-associated (Cas) protein
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US12297489B2 (en) 2017-05-17 2025-05-13 CureVac Manufacturing GmbH Method for determining at least one quality parameter of an RNA sample
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
ES2913457T3 (en) 2017-06-30 2022-06-02 Inscripta Inc Automated Cell Processing Methods, Modules, Instruments and Systems
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11970720B2 (en) 2017-08-22 2024-04-30 Salk Institute For Biological Studies RNA targeting methods and compositions
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
RU2020115287A (en) * 2017-10-19 2021-11-19 Куревак Аг NEW MOLECULES OF ARTIFICIAL NUCLEIC ACIDS
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
CN111886336B (en) 2017-11-01 2025-05-02 加利福尼亚大学董事会 CASZ compositions and methods of use
US12227753B2 (en) 2017-11-01 2025-02-18 The Regents Of The University Of California CasY compositions and methods of use
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
CN111511928A (en) 2017-12-21 2020-08-07 库瑞瓦格股份公司 Linear double-stranded DNA coupled to a single support or tag and method for preparing the linear double-stranded DNA
EP3755792A4 (en) * 2018-02-23 2021-12-08 Pioneer Hi-Bred International, Inc. NEW CAS9 ORTHOLOGIST
JP7399876B2 (en) * 2018-04-16 2023-12-18 ジョージア テック リサーチ コーポレーション mRNA-driven expression of RNA editors for disease treatment
CN112292395A (en) 2018-04-17 2021-01-29 库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
KR20210027368A (en) 2018-06-28 2021-03-10 큐어백 아게 R&A bioreactor for in vitro transcription
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
CN112638494B (en) 2018-06-30 2022-01-21 因思科瑞普特公司 Apparatus, modules and methods for improved detection of editing sequences in living cells
WO2020023529A1 (en) * 2018-07-24 2020-01-30 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
RU2706298C1 (en) * 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" PaCas9 NUCLEASE
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment
WO2020081808A1 (en) * 2018-10-18 2020-04-23 Chan Zuckerberg Biohub, Inc. Methods and compositions involving thermostable cas9 protein variants
CA3116334A1 (en) * 2018-10-22 2020-04-30 University Of Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020098968A1 (en) * 2018-11-12 2020-05-22 Aptarion Biotech Ag Cxcl8 binding nucleic acids
CN113710799B (en) * 2018-11-28 2024-11-12 克里斯珀医疗股份公司 Optimized mRNA encoding Cas9 for use in LNPs
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
WO2020142739A1 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. COMPOSITIONS AND METHODS FOR DETECTING MODIFIED NUCLEIC ACIDS AND AMPLIFYING ssDNA
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
EP3924477A4 (en) * 2019-02-14 2023-03-29 Metagenomi, Inc. Enzymes with ruvc domains
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CN113631713A (en) 2019-03-25 2021-11-09 因思科瑞普特公司 Simultaneous multiplex genome editing in yeast
US20220213456A1 (en) * 2019-04-30 2022-07-07 Emendobio Inc. Novel omni crispr nucleases
WO2020247587A1 (en) 2019-06-06 2020-12-10 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
PE20220256A1 (en) 2019-06-07 2022-02-21 Scribe Therapeutics Inc ARTIFICIAL CASX SYSTEMS
US20220347115A1 (en) * 2019-07-12 2022-11-03 Duke University Nanoparticle systems for targeted delivery of crispr/cas13 and methods of using same
CA3147783A1 (en) * 2019-08-12 2021-02-18 Tyson D. BOWEN Rna-guided nucleases and active fragments and variants thereof and methods of use
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
KR102776469B1 (en) * 2019-12-10 2025-03-05 인스크립타 인코포레이티드 Novel MAD nuclease
CA3161392A1 (en) * 2019-12-16 2021-06-24 David DE VLEESSCHAUWER Codon-optimized cas9 endonuclease encoding polynucleotide
CA3157127A1 (en) 2019-12-18 2021-06-24 Aamir MIR Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
CN115135370A (en) 2020-01-27 2022-09-30 因思科瑞普特公司 Electroporation module and instrument
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN115315519A (en) * 2020-02-28 2022-11-08 辉大(上海)生物科技有限公司 VI-E and VI-F CRISPR-Cas systems and their uses
JP7546689B2 (en) 2020-03-31 2024-09-06 メタゲノミ，インク． Class 2 Type II CRISPR System
WO2021211598A1 (en) * 2020-04-14 2021-10-21 University Of Massachusetts Dcas13-mediated therapeutic rna base editing for in vivo gene therapy
TW202208626A (en) 2020-04-24 2022-03-01 美商生命編輯公司 Rna-guided nucleases and active fragments and variants thereof and methods of use
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
EP4165177A4 (en) * 2020-05-08 2024-08-28 Metagenomi, Inc. Enzymes with ruvc domains
EP4162039A4 (en) 2020-06-04 2024-12-11 Emendobio Inc. Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
WO2022098681A2 (en) * 2020-11-03 2022-05-12 Caspr Biotech Corporation Novel class 2 crispr-cas rna-guided endonucleases
AU2021374941A1 (en) * 2020-11-05 2023-06-15 New York University Enhancement of predictable and template-free gene editing by the association of cas with dna polymerase
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
CA3201258A1 (en) 2020-12-03 2022-06-09 Sean Higgins Engineered class 2 type v crispr systems
KR20230164648A (en) 2020-12-22 2023-12-04 큐어백 에스이 RNA vaccines against SARS-CoV-2 variants
US11306298B1 (en) * 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
AU2022205595A1 (en) * 2021-01-05 2023-08-17 Dxlab Inc. Methods for detection of nucleic acids
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
KR20230142740A (en) * 2021-02-08 2023-10-11 에멘도바이오 인코포레이티드 OMNI-103 CRISPR Nuclease
US12091688B2 (en) 2021-02-08 2024-09-17 Emendobio Inc. OMNI-103 CRISPR nuclease
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
KR20240004618A (en) * 2021-04-30 2024-01-11 메타지노미, 인크. Enzymes with RUVC domains
WO2022272294A1 (en) * 2021-06-23 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for efficient retron recruitment to dna breaks
AU2022325958A1 (en) * 2021-08-13 2024-03-21 Emendobio Inc. Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases
EP4392561A1 (en) 2021-08-27 2024-07-03 Metagenomi, Inc. Enzymes with ruvc domains
WO2023031394A1 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4437096A4 (en) 2021-11-24 2025-09-24 Metagenomi Inc ENDONUCLEASE SYSTEMS
JP2024542883A (en) * 2021-12-01 2024-11-18 エメンドバイオ・インコーポレイテッド Engineered high fidelity OMNI-79 nuclease variants
CN119095968A (en) * 2021-12-17 2024-12-06 比姆医疗股份有限公司 CRISPR enzymes, methods, systems and uses thereof
EP4466349A1 (en) * 2022-01-24 2024-11-27 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
JP2025505148A (en) * 2022-02-02 2025-02-21 インスクリプタ， インコーポレイテッド Nucleic acid-guided nickase fusion proteins
CN114807104B (en) * 2022-04-11 2024-02-20 西南大学 Klebsiella pneumoniae phage lytic enzyme and its preparation method and application
WO2024042165A2 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
KR20250130360A (en) * 2022-12-28 2025-09-01 에멘도바이오 인코포레이티드 OMNI-355 CRISPR nuclease
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024211883A1 (en) * 2023-04-07 2024-10-10 The General Hospital Corporation Click-to-install genome editing
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025045247A1 (en) * 2023-08-31 2025-03-06 Geneditbio Limited Nucleic acids encoding crispr-associated proteins and uses thereof
WO2025132815A1 (en) * 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
EP1903054A3 (en) 2001-06-05 2008-07-23 CureVac GmbH Pharmaceutical compound containing a stabilised mRNA which is optimised for translation in its coded areas
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
DE102006035618A1 (en) 2006-07-31 2008-02-07 Curevac Gmbh New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
DE102006061015A1 (en) 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
JP5749494B2 (en) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
RU2545701C2 (en) 2008-01-31 2015-04-10 Куревак Гмбх NUCLEIC ACIDS OF FORMULA (I) (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENTS/ADJUVANTS
EP3112477A1 (en) 2008-02-28 2017-01-04 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PL2350043T3 (en) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
CN104910025B (en) 2008-11-07 2019-07-16 麻省理工学院 Alkamine lipid and its purposes
CN105709229B (en) 2008-11-10 2020-07-28 阿布特斯生物制药公司 Novel lipids and compositions for delivery of therapeutic agents
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
KR20210031549A (en) 2009-05-05 2021-03-19 알닐람 파마슈티칼스 인코포레이티드 Lipid compositions
KR102374518B1 (en) 2009-06-10 2022-03-16 알닐람 파마슈티칼스 인코포레이티드 Improved lipid formulation
KR20120097484A (en) 2009-07-31 2012-09-04 에트리스 게엠베하 Rna with a combination of unmodified and modified nucleotides for protein expression
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
JP6043278B2 (en) 2010-04-09 2016-12-14 パシラ ファーマシューティカルズ インコーポレーテッド Method for making multivesicular liposomes, method for preparing large diameter synthetic membrane vesicles, and evaporation apparatus
KR101967411B1 (en) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 Biodegradable lipids for the delivery of active agents
RU2625546C2 (en) 2010-07-06 2017-07-14 Новартис Аг Cationic emulsions "oil-in-water"
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
US20130189351A1 (en) 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
RS63329B1 (en) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
LT4066819T (en) 2010-08-31 2023-04-11 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2729126B1 (en) 2011-07-06 2020-12-23 GlaxoSmithKline Biologicals SA Liposomes having useful n:p ratio for delivery of rna molecules
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CA2859452C (en) * 2012-03-27 2021-12-21 Curevac Gmbh Artificial nucleic acid molecules for improved protein or peptide expression
SG10201607966UA (en) * 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules comprising a 5'top utr
AU2013242403B2 (en) 2012-03-27 2018-10-18 Curevac Ag Artificial nucleic acid molecules
EP2831240B1 (en) * 2012-03-27 2017-11-15 CureVac AG Artificial nucleic acid molecules comprising a 5'top utr
ES2719598T3 (en) 2012-05-25 2019-07-11 Curevac Ag Reversible immobilization and / or controlled release of nucleic acids contained in nanoparticles by polymeric coatings (biodegradable)
FI3597749T3 (en) * 2012-05-25 2023-10-09 Univ California METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
BR112015022061B8 (en) 2013-03-14 2023-12-26 Caribou Biosciences Inc Genetically engineered single-stranded guide nucleic acid targeting nucleic acid, polynucleotide, method for cleaving a target nucleic acid and for ligating a target nucleic acid, composition and kit
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
EP3011029B1 (en) * 2013-06-17 2019-12-11 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
PT3019619T (en) * 2013-07-11 2021-11-11 Modernatx Inc COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING SYNTHETIC CRISPR AND SGARN-RELATED PROTEINS AND METHODS OF USE
AU2014310933B2 (en) 2013-08-21 2020-05-14 CureVac SE Method for increasing expression of RNA-encoded proteins
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
WO2015024664A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
EA037217B1 (en) 2013-08-21 2021-02-20 Куревак Аг Composition and vaccine for treating lung cancer
CA2915712A1 (en) 2013-08-21 2015-02-26 Margit SCHNEE Rabies vaccine
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
KR102095085B1 (en) 2013-11-18 2020-03-31 아크투루스 쎄라퓨틱스, 인크. ionizable cationic lipid for rna delivery
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
AU2014375404C1 (en) 2013-12-30 2020-11-19 CureVac Manufacturing GmbH Methods for RNA analysis
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
MX372790B (en) 2013-12-30 2020-07-03 CureVac SE ARTIFICIAL NUCLEIC ACID MOLECULES.
EP3116535B1 (en) 2014-03-12 2019-08-07 CureVac AG Combination of vaccination and ox40 agonists
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2015273933B2 (en) 2014-06-10 2021-02-11 CureVac Manufacturing GmbH Methods and means for enhancing RNA production
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3708668B1 (en) 2014-12-12 2022-07-27 CureVac AG Artificial nucleic acid molecules for improved protein expression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
EP3233132A4 (en) 2014-12-19 2018-06-27 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016107877A1 (en) * 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
WO2016170176A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2016174227A1 (en) 2015-04-30 2016-11-03 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
SG11201708867UA (en) 2015-04-30 2017-11-29 Curevac Ag Immobilized poly(n)polymerase
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
JP6893177B2 (en) 2015-05-15 2021-06-23 キュアバック アーゲー PRIME-BOOST REGIMENS containing administration of at least one mRNA construct
US10729654B2 (en) 2015-05-20 2020-08-04 Curevac Ag Dry powder composition comprising long-chain RNA
SG10201910431RA (en) 2015-05-20 2020-01-30 Curevac Ag Dry powder composition comprising long-chain rna
DE202016009003U1 (en) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Composition comprising in vitro transcribed RNA obtainable by a method for the production and purification of RNA with at least one step with a tangential flow filtration
WO2016193226A1 (en) 2015-05-29 2016-12-08 Curevac Ag Method for adding cap structures to rna using immobilized enzymes
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
WO2017001058A1 (en) 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
EP3699288A1 (en) 2015-08-07 2020-08-26 CureVac AG Process for the in vivo production of rna in a host cell
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
ES2924739T3 (en) * 2015-08-28 2022-10-10 Curevac Ag artificial nucleic acid molecules
SI3352584T1 (en) 2015-09-21 2021-09-30 Trilink Biotechnologies, Llc Compositions and methods for synthesizing 5'-capped rnas
WO2017064146A1 (en) 2015-10-12 2017-04-20 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
HUE061564T2 (en) 2015-10-28 2023-07-28 Acuitas Therapeutics Inc New lipids and lipid nanoparticle formulations for nucleic acid delivery
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
WO2017081082A2 (en) 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
WO2017108087A1 (en) 2015-12-21 2017-06-29 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
DK3319622T3 (en) 2015-12-22 2020-05-04 Curevac Ag PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017137095A1 (en) 2016-02-12 2017-08-17 Curevac Ag Method for analyzing rna
US20190049414A1 (en) 2016-02-15 2019-02-14 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3433361A1 (en) 2016-03-24 2019-01-30 CureVac AG Immobilized inorganic pyrophosphatase (ppase)
EP3777881A1 (en) 2016-04-22 2021-02-17 CureVac AG Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017191258A1 (en) 2016-05-04 2017-11-09 Curevac Ag Influenza mrna vaccines
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MY201498A (en) 2016-05-18 2024-02-27 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
MA45053A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
EP3896164A1 (en) 2016-05-18 2021-10-20 ModernaTX, Inc. Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3468612A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
CA3023174A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
US20190185859A1 (en) 2016-08-19 2019-06-20 Curevac Ag Rna for cancer therapy
KR20240150810A (en) 2016-10-26 2024-10-16 큐어백 에스이 Lipid nanoparticle mrna vaccines
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US12297489B2 (en) 2017-05-17 2025-05-13 CureVac Manufacturing GmbH Method for determining at least one quality parameter of an RNA sample
EP4494652A3 (en) 2017-07-04 2025-05-14 CureVac SE Cancer rna-vaccine
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
IL311278A (en) * 2017-09-29 2024-05-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing
RU2020115287A (en) 2017-10-19 2021-11-19 Куревак Аг NEW MOLECULES OF ARTIFICIAL NUCLEIC ACIDS
SG11202003247RA (en) 2017-11-08 2020-05-28 Curevac Ag Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
CN111511928A (en) 2017-12-21 2020-08-07 库瑞瓦格股份公司 Linear double-stranded DNA coupled to a single support or tag and method for preparing the linear double-stranded DNA
US20210361761A1 (en) 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CN112292395A (en) 2018-04-17 2021-01-29 库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
US20210260178A1 (en) 2018-06-27 2021-08-26 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
KR20210027368A (en) 2018-06-28 2021-03-10 큐어백 아게 R&A bioreactor for in vitro transcription
TW202039534A (en) 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
EP3897702A2 (en) 2018-12-21 2021-10-27 CureVac AG Rna for malaria vaccines
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis

Also Published As

Publication number Publication date
BR112019015244A2 (en) 2020-04-14
US11739335B2 (en) 2023-08-29
MX2019011215A (en) 2020-02-12
WO2018172556A1 (en) 2018-09-27
US20210403925A1 (en) 2021-12-30
KR102842382B1 (en) 2025-08-04
US20230332163A1 (en) 2023-10-19
EP3601576A1 (en) 2020-02-05
CN110914433A (en) 2020-03-24
JP2020513824A (en) 2020-05-21
CA3050616A1 (en) 2018-09-27
JP2024038121A (en) 2024-03-19
US12371699B2 (en) 2025-07-29
RU2019132890A3 (en) 2021-07-14
AU2018240515B2 (en) 2024-07-25
US20250304976A1 (en) 2025-10-02
SG10202110491PA (en) 2021-11-29
KR20190133699A (en) 2019-12-03
AU2018240515A1 (en) 2019-08-01
RU2019132890A (en) 2021-04-26

Similar Documents

Publication Publication Date Title
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201806340YA (en) Zika virus vaccine
SG11201907846VA (en) Therapeutic rna
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201910191RA (en) A peptide capable of forming a gel for use in tissue engineering and bioprinting
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载